Nikkei 225 Component
|Industry||Biotechnology & Pharmaceuticals|
|Founded||Osaka, Japan (March 17, 1878 )|
|Founder||Gisaburo Shiono Sr.|
|Headquarters||1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan|
|Revenue|| $ 3.009 billion USD (FY 2012)|
(¥ 282.904 billion JPY) (FY 2012)
| $709.79 million USD (FY 2012)|
(¥ 66.728 billion JPY) (FY 2012)
Number of employees
|Consolidated : 6,082|
|Footnotes / references|
Shionogi & Company, Limited (塩野義製薬株式会社, Shionogi Seiyaku Kabushiki Kaisha) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.